Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers

• Main Authors: Andreas Becker (Author), Emily C. Martin (Author), David Y. Mitchell (Author), Roland Grenningloh (Author), Andrew T. Bender (Author), Julien Laurent (Author), Harald Mackenzie (Author), Andreas Johne (Author)
• Format: Book
• Published: Wiley, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Bruton's tyrosine kinase (BTK) is a key regulator of B cell receptor and Fc receptor signaling, and a rational therapeutic target for autoimmune diseases. This first‐in‐human phase I, double‐blind, placebo‐controlled trial investigated the safety, tolerability, pharmacokinetics (PK), target occ...